Novozymes As Stock Performance
| NVZMY Stock | USD 64.28 0.65 1.00% |
Novozymes has a performance score of 5 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 0.33, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Novozymes' returns are expected to increase less than the market. However, during the bear market, the loss of holding Novozymes is expected to be smaller as well. Novozymes AS right now secures a risk of 1.64%. Please verify Novozymes AS kurtosis, market facilitation index, and the relationship between the semi variance and rate of daily change , to decide if Novozymes AS will be following its current price movements.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Novozymes AS are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak primary indicators, Novozymes may actually be approaching a critical reversion point that can send shares even higher in February 2026. ...more
Novozymes |
Novozymes Relative Risk vs. Return Landscape
If you would invest 6,037 in Novozymes AS on October 30, 2025 and sell it today you would earn a total of 391.00 from holding Novozymes AS or generate 6.48% return on investment over 90 days. Novozymes AS is currently producing 0.1176% returns and takes up 1.637% volatility of returns over 90 trading days. Put another way, 14% of traded pink sheets are less volatile than Novozymes, and 98% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Novozymes Target Price Odds to finish over Current Price
The tendency of Novozymes Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 64.28 | 90 days | 64.28 | about 21.63 |
Based on a normal probability distribution, the odds of Novozymes to move above the current price in 90 days from now is about 21.63 (This Novozymes AS probability density function shows the probability of Novozymes Pink Sheet to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon Novozymes has a beta of 0.33. This indicates as returns on the market go up, Novozymes average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Novozymes AS will be expected to be much smaller as well. Additionally Novozymes AS has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Novozymes Price Density |
| Price |
Predictive Modules for Novozymes
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Novozymes AS. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Novozymes Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Novozymes is not an exception. The market had few large corrections towards the Novozymes' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Novozymes AS, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Novozymes within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.0002 | |
β | Beta against Dow Jones | 0.33 | |
σ | Overall volatility | 1.72 | |
Ir | Information ratio | -0.03 |
Novozymes Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Novozymes Pink Sheet often depends not only on the future outlook of the current and potential Novozymes' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Novozymes' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 278.7 M | |
| Cash And Short Term Investments | 1.1 B |
Novozymes Fundamentals Growth
Novozymes Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Novozymes, and Novozymes fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Novozymes Pink Sheet performance.
| Return On Equity | 0.28 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 14.47 B | |||
| Shares Outstanding | 276.6 M | |||
| Price To Earning | 34.25 X | |||
| Price To Book | 6.12 X | |||
| Price To Sales | 0.80 X | |||
| Revenue | 17.55 B | |||
| EBITDA | 6.11 B | |||
| Cash And Equivalents | 1.01 B | |||
| Cash Per Share | 3.67 X | |||
| Total Debt | 7.31 B | |||
| Debt To Equity | 0.58 % | |||
| Book Value Per Share | 50.02 X | |||
| Cash Flow From Operations | 4.01 B | |||
| Earnings Per Share | 1.90 X | |||
| Total Asset | 27.98 B | |||
| Retained Earnings | 9.99 B | |||
| Current Asset | 6.08 B | |||
| Current Liabilities | 3.41 B | |||
About Novozymes Performance
Evaluating Novozymes' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Novozymes has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Novozymes has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Novozymes AS produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark. Novozymes Unspn is traded on OTC Exchange in the United States.Things to note about Novozymes AS performance evaluation
Checking the ongoing alerts about Novozymes for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Novozymes AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Evaluating Novozymes' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Novozymes' pink sheet performance include:- Analyzing Novozymes' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Novozymes' stock is overvalued or undervalued compared to its peers.
- Examining Novozymes' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Novozymes' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Novozymes' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Novozymes' pink sheet. These opinions can provide insight into Novozymes' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Novozymes Pink Sheet Analysis
When running Novozymes' price analysis, check to measure Novozymes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novozymes is operating at the current time. Most of Novozymes' value examination focuses on studying past and present price action to predict the probability of Novozymes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novozymes' price. Additionally, you may evaluate how the addition of Novozymes to your portfolios can decrease your overall portfolio volatility.